Management of cutaneous side-effects of cetuximab thera- py in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24(4):453-459.Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad ...
cetuximabwas initially slowed because of concerns overclinical trialdesign and outcome data management (Reynolds, 2002), the antibody was approved for use in the treatment of advancedmetastatic colorectal cancerin February 2004. Similar totrastuzumab, the development of cetuximab also included an ...
dations for toxicity management. Clin J Oncol Nurs 2005; 9: 332-338. 11. Busam, K. J., Capodieci, C., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Brit...
Cerman J, Melichar B, Cermanova M, Solichova D (2008) Management of severe infusion reactions after cetuximab. Acta Oncol 47:1609–1611. : 10.1080/02841860802123204Jaroslav Cerman,Bohuslav Melichar,Melanie Cermanová,Dagmar Solichová.Management of severe infusion reactions after cetuximab[J]. ...
Talk to your doctor or nurse about management of skin problems Your doctor or nurse may suggest the use of moisturizing lotion to help keep skin moist They may also suggest cool compresses to relieve itching Being out in the sun may make skin problems worse. People receiving ERBITUX should we...
Many areas are still under active investigation such as administration schedules, their efficacy in comparison with bevacizumab, their role in adjuvant therapy, molecular predictors, and management of side effects.doi:10.1177/0091270010395940Benoit
The side effects of cetuximab included rash; itching; nail changes; headache; diarrhea; and respiratory, skin, and mouth infections. Cetuximab has been associated with serious and potentially life-threatening infusion reactions and heart attack. This is the first approval of cetuximab for use in...
Keywords: SCCHN, cetuximab, recurrent metastatic, locoregionally advanced, chemoradiation Introduction to the management issues in the treatment of head and neck cancer More than 90% of head and neck cancers are of squamous cell histology and originate in the lip, oral cavity, oropharynx, ...
(EGFR) gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangement,4,5 have opened a new era in the management of lung cancer.6 However, due to the lack of therapeutic means, non-resectable and recurrent lung adenocarcinoma mostly have an unfavorable prognosis and a low survival ...
Keywords: SCCHN, cetuximab, recurrent metastatic, locoregionally advanced, chemoradiation Introduction to the management issues in the treatment of head and neck cancer More than 90% of head and neck cancers are of squamous cell histology and originate in the lip, oral cavity, oropharynx, ...